StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
HEALTH.HE$0.96+6.46%
Fair $0.96+0.0%

HEALTH.HE

Nightingale Health Oyj

Healthcare / Health Information ServicesHelsinki

$0.96

+0.06 (+6.46%)

Fairly Valued+0.0%Fair Value $0.96Fund rank 31/100 · Data gapFallback financials|
SA 23/D
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 25%

FCF escenarios

weak_data · normalized FCF $-13.0M · quality 72.7/100

Data gap 31/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 39/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

23/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -27.9%, below the 5% threshold
Thesis & Journal · HEALTH.HELocal privado en este navegador · Nightingale Health Oyj
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$58M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-27.9%

↓

Gross Margin

75.4%

↑

Debt/Equity

0.05

↓
52-Week Range$1
$1$3

TradingView lightweight chart

HEALTH.HE price, volumen y niveles de valoración

Último $0.956Periodo -81.4%
Fair value: $0.956

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+26.6%

FCF CAGR

—

FCF margin

-303.9%

FCF / Net income

0.77x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $4.7M · net income $-18.5M · FCF $-14.3M

2022-FY → 2025-FY

Gross margin

75.4%+20.2% pts

Operating margin

-413.4%+176.9% pts

Net margin

-393.4%+302.3% pts

FCF margin

-303.9%+348.4% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$4.7M$4.7M$4.4M$4.2M$2.3M
Net Income$-18.5M$-18.5M$-17.5M$-18.1M$-16.1M
EBITDA$-8.8M$-8.8M$-8.4M$-11.4M$-11.2M
EPS-0.31-0.31-0.29-0.30-0.27
Gross Margin75.4%75.4%66.5%85.9%55.2%
Operating Margin-413.4%-413.4%-427.8%-447.1%-590.3%
Net Margin-393.4%-393.4%-400.7%-432.4%-695.7%
Balance Sheet
Debt/Equity0.050.050.030.050.07
Current Ratio8.538.53———
Cash Flow
Free Cash Flow$-14.3M$-14.3M$-13.0M$-11.7M$-15.1M
Returns
ROE-27.9%-27.9%-21.1%-18.6%-14.4%
Valuation
P/B0.870.871.790.520.98
Growth & Yield
Revenue Growth7.7%7.7%4.2%80.8%—
EPS Growth-6.9%-6.9%3.3%-11.1%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -66.3%

Total return

-66.3%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.29 → -0.31

Residual

-66.3%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-66.3%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.